With more than 30 years of experience in the biopharmaceutical industry and rich experience in industrial development and business management, Dr. Yu returned to China in 2009 and led a team to establish CanSinoBIO, which focuses on the research, development, production and marketing of high-quality human vaccines. Over the past ten years, Dr. Yu has led his team in setting up five major technology platforms and formed a highly competitive product pipeline, including a number of innovative vaccine products for the prevention of more than 10 indications, including meningitis, pneumonia, pertussis, diphtheria, tetanus, COVID-19, Ebola virus disease, herpes zoster, and tuberculosis, etc., as well as innovative R&D collaborations with a number of research institutes around the world.

Currently, CanSinoBIO has launched the following products: Menhycia®, Asia's first Quadrivalent meningococcal conjugate vaccine;China's first dual-carrier (CRM197/TT)13-valent Pneumococcal Polysaccharide Conjugate Vaccine iPneucia® , Menphecia®, a bivalent conjugate vaccine with a Group A and C meningococcal polysaccharide conjugate vaccine (CRM197 vector); Convidecia®, a recombinant coronavirus vaccine that has been recognized by the World Health Organization (WHO); Convidecia® Air®, the world's first coronavirus vaccine for inhalation; and Asia's only recombinant vaccine against Ebola Virus Disease. And many other global innovative vaccines and a number of China's first vaccines are under the research and clinical stages.

Under Dr. Yu's leadership, CanSinoBIO has successfully completed its H-share market listing on the main board of the Hong Kong Stock Exchange and its A-stock listing on the Science and Technology Innovation Board of the Shanghai Stock Exchange in 2019 and 2020, respectively, making it the first “A+H” vaccine stock in China. The company continues to transform and grow through commercialization and internationalization, writing a new chapter that will lead China to the forefront of global public health.